Posts Tagged ‘Obesity’


Takeda buys into Amylin‘s weight-loss drug portfolio – Takeda will pay $75 million upfront for medicines including Amylin’s pramlintide/metreleptin and davalintide, in the second phase of testing needed for U.S. regulatory approval, Osaka- based Takeda and San Diego-based Amylin said in a statementmore Plus, quickie update on three other anti-obesity drugs being developed by various companies.

New lupus treatment (HGS/Glaxo) looking promising on pathway to approval – Human Genome Sciences Inc said its experimental lupus drug Benlysta was successful in a second large clinical trial, paving the way for approval of the first new treatment for the disease in 50 yearsmore

Vertex HepC drug cures 80%The hepatitis C cure rates of greater than 80% across all four patient groups of the study are also the highest ever recorded in any telaprevir study to date and exceed the cure rates reported in separate studies of boceprevir, a competing hepatitis C drug under development by Schering-Ploughmore

Let’s investigate: Amgen and Shire are the latest.


Meetings. Event planning and execution, logistics, training. We can match you up with the ideal partner(s). Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.


Not counting on blockbusters – changes, and the future, at Sanofi-Aventis.


Bayer turns its headquarters into a giant billboard. Pretty eye-catching (watch the video clip).


Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Social Networking in our industry*. PharmaExec looks at the use of social networking platforms among physicians. And, an abstract of Manhattan Research‘s findings (scroll past TOC to read excerpt). A new kind of social network has been gaining traction among doctors – namely, physician-only communities where doctors can exchange ideas, opinions, and information about treatments with their peers…

Earnings reports: Abbott Labs comes in strong. J&J, maybe not so much. King, looking at increasing threats from generics.

Obesity may be a top health concern, but the drugs developed to treat it aren’t getting rave reviews.

* As a long-time user of social media applications, I have a deep interesting in the use of these approaches in pharma. The challenges of social media use in a highly-regulated industry are well-documented and problematic. But it won’t be an option in the future. Every pharma will have to deal with the FACT that social media use is increasingly pervasive, and responsible PR/Communications/Marketing must come to grips with it.


Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs.

Reblog this post [with Zemanta]

Read Full Post »